2022.12.14Vol.4 No.8 PMDA The English version of Q&A on Post-marketing adverse reaction reporting and Clinical Trial adverse reaction reporting in accordance with the MHLW/FDA E2B (R3) Implementation Guide (English version 24-Jun-2022) has been uploaded on the HiroPharma Reference Page.
